serotonin syndrome การใช้

• Serotonin syndrome has been reported when trazodone was abruptly replaced with moclobemide.
• The differential diagnosis is similar to that of hyperthermia, and includes serotonin syndrome.
• Following appropriate medical management, serotonin syndrome is generally associated with a favorable prognosis.
• Many medications may have been incorrectly thought to cause serotonin syndrome.
• The reasons for serotonin syndrome are complicated and not fully understood.
• Serotonin syndrome encompasses a wide range of clinical findings.
• SNRIs, such as venlafaxine in combination with moclobemide have also been associated with serotonin syndrome.
• The use of naratriptan with MAOIs and serotonergic drugs may result in the life-threatening serotonin syndrome.
• Tryptophan supplements should not be consumed with MAOIs as the potentially fatal serotonin syndrome may result.
• There is no laboratory test for serotonin syndrome.
• In cases of serotonin syndrome caused by monoamine oxidase inhibitors oxygenation will not help to dispatch serotonin.
• Features which distinguish NMS from serotonin syndrome include bradykinesia, muscle rigidity, and elevated white blood cell count.
• Several deaths have been reported due to drug interaction-related serotonin syndrome such as the case of Libby Zion.
• Side effects may include serotonin syndrome.
• The norpethidine metabolite was found to have serotonergic effects, so pethidine could, unlike most opioids, contribute to serotonin syndrome.
• Thus, the presence of arrythmia, abnormal echocardiograms, or chest pain indicates an adrenergic crisis and rules out serotonin syndrome.
• SSRIs, including citalopram, can increase the risk of bleeding, especially when coupled with aspirin, MAOIs, owing to a potential for serotonin syndrome.
• Tetanus, neuroleptic malignant syndrome, malignant hyperpyrexia, chronic spinal interneuronitis, serotonin syndrome, Multiple sclerosis, Parkinson's disease, and Isaacs syndrome should also be excluded.
• The FDA drug label carries a warning of the risk of serotonin syndrome when rasagiline is used with antidepressants or with meperidine.
• The level of catalepsy did not increase with chronic dosing, and there was no evidence for serotonin syndrome at clinically relevant doses.